Research programme: microRNA therapeutics - miRagen Therapeutics

Drug Profile

Research programme: microRNA therapeutics - miRagen Therapeutics

Alternative Names: AntimiR-15; AntimiR-155; AntimiR-208; AntimiRNA-15; MGN 7455; MGN-4893; miR-143/145; miR-15/195; miR-206; miR-208; miR-208/499; miR-29; miR-499; miR-92/126; MIRG-9103; miRNA-145 inhibitor; MRG-107

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Glasgow; University of Texas Southwestern Medical Center
  • Class MicroRNAs
  • Mechanism of Action MIRN145-microRNA-inhibitors; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Hypertrophic cardiomyopathy; Ischaemia; Peripheral arterial disorders; Unspecified
  • No development reported Heart failure; Postmyocardial infarction
  • Discontinued Coronary artery restenosis; Fibrosis; Polycythaemia vera; Pulmonary arterial hypertension

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postmyocardial-infarction in USA (Parenteral)
  • 08 Jun 2016 Preclinical trials in Undefined indication in USA (Parenteral) before June 2016 (miRagen Therapeutics pipeline; June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top